An Indian Paediatric Oncology Group collaborative multicentre treatment protocol for children and adolescents with relapsed acute lymphoblastic leukaemia (InPOG ALL R1)
● Principal Investigator: Prof. Vaskar Saha
● To Assess the feasibility of a uniform strategy to manage first relapse ALL at multiple centres across India
● To Evaluate the event free survival of SR and HR rALL patients with this protocol
1. All patients with first relapse of BCP ALL or T ALL
2. Age < 18 years
1. Incomplete diagnostic workup
2. Refusal of consent
This is a protocol for treating children with relapsed ALL in India, based on over 20 years of experience. The approach was piloted at the Tata Medical Centre, Kolkata with satisfactory outcomes and tolerable toxicities. The study seeks to assess the feasibility of standardising the approach to relapsed ALL across multiple centres in India and obtain an understanding of the real-world situation of managing such patients in India. The protocol is risk stratified, incorporates a novel agent (Bortezomib) and seeks to improve remission rates, MRD responses and outcomes without increasing toxicity. This is a single arm, phase III interventional study.